10-K: BioScience Health soars 208%, posts 2025 profit

BioScience Health Innovations reported 2025 revenue up 208% to $5.69M and net income of $0.64M, detailed capital-raising and uplist plans, and disclosed material internal control weaknesses.

Summary

• Revenue grew 208% year over year to $5,688,717 in 2025 (2024: $1,844,966).
• Net income rose to $642,090 in 2025 (2024: $87,000), with net margin expanding from 4.7% to 11.3%.
• Gross profit was $3,240,717, implying a gross margin of approximately 57.0% in 2025.
• Operating income was $719,051; income tax expense was $76,961.
• Cash provided by operating activities was $172,178; year-end cash was $661,925.
• Total assets were $1,707,181; total current liabilities were $229,851; stockholders’ equity was $1,477,330.
• Working capital at 12/31/2025 was $1,328,807.
• Shares outstanding at 12/31/2025 were 10,979,058 common shares; 140,000 Series A preferred shares remained outstanding.
• A 1-for-4 reverse stock split and increase in authorized common shares to 250,000,000 were effected on 9/10/2025.
• Significant related-party activity: $2,665,950 of inventory purchased from Ageless Holdings, LLC in 2025; net overpayment to related parties of $137,717 at 12/31/2025.
• Disclosure controls and internal control over financial reporting were deemed ineffective due to material weaknesses (inadequate control environment, lack of segregation of duties, limited IT and GAAP/SEC resources).
• Company invested in Oracle NetSuite ERP and consumer-facing web upgrades; plans to implement NetSuite AI tools in 2026.
• Announced a multi-phase capital strategy: a $1.5M Regulation A offering (with $388,067 raised by 3/30/2026) and a planned additional $5–$7.5M raise tied to a major exchange uplist.
• Entered a 15-month facility lease on 12/1/2025 and prepaid the rent ($65,610), recording a right-of-use asset.
• Outlook initiatives include pharmacy partnerships, an Amazon operations pivot to Rebelution/Growvana, MODS Max platform licensing, and potential GLP-1 oral delivery under 503A and 505(b)(2) pathways.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as moderately positive: strong growth and profitability with clear scaling plans, tempered by material control weaknesses, related-party concentration, penny stock/OTC risks, and impending dilution.

Positives

• Triple-digit growth: 2025 revenue up 208% to $5.69M.
• Improved profitability: net income of $642,090 (net margin ~11.3%) vs. $87,000 in 2024.
• Gross margin robust at ~57.0% in 2025.
• Positive operating cash flow of $172,178 and solid working capital of $1,328,807 at year-end.
• Operational upgrades (Oracle NetSuite ERP, website enhancements) support scalability and public company readiness.
• Clear multi-channel growth strategy (DTC, wholesale, pharmacy partnerships, Amazon pivot).
• Strengthening IP position with multiple U.S. and international patent applications pending.

Negatives

• Disclosure controls and internal control over financial reporting were ineffective, with multiple material weaknesses identified.
• High reliance on related-party transactions in 2025, including $2,665,950 of inventory purchases from Ageless Holdings, LLC and related-party advances/repayments.
• Penny stock status on OTC Pink and limited trading liquidity; 53 record holders as of 12/31/2025.
• Potential shareholder dilution from ongoing and planned capital raises (Reg A plus $5–$7.5M uplist financing).
• Cybersecurity program not yet formalized; no specific policies implemented to date.

Risks

• Need for additional capital could lead to dilution and/or unfavorable terms; future securities may have preferences that subordinate existing holders.
• OTC Pink quotation, penny stock rules, and FINRA suitability requirements constrain liquidity and may depress the stock price.
• Amended Rule 15c2-11 could limit quotations or raise compliance costs if current public information is not maintained, affecting liquidity and price.
• Stock price volatility risk due to limited market, sporadic trading, and potential block sales by shareholders.
• Authority to issue preferred stock with superior rights could deter takeovers and adversely affect common shareholders.
• Material weaknesses in internal control (inadequate control environment, lack of segregation of duties, limited accounting and IT controls) increase the risk of misstatement.
• Cybersecurity: no material incidents identified, but no specific monitoring/management policies implemented as of the report date.
• Regulatory uncertainty: peptide reclassification (announced 2/27/2026) is pending FDA publication; timelines and outcomes may affect commercialization plans.

Future Outlook

Management plans to complete a $1.5M Reg A raise (with $388,067 received by 3/30/2026), pursue a major exchange uplist with an additional $5–$7.5M capital raise, evaluate a reverse stock split for exchange compliance, scale via pharmacy partnerships and an Amazon commercialization pivot, and monetize the MODS Max delivery platform (including potential GLP-1 oral delivery through 503A and 505(b)(2) pathways).

Management Comments

• “We are excited for what Rebelution and Growvana can help us accomplish through their Amazon prowess and AI-driven technology... this partnership gives us the infrastructure to bring those innovations to millions of consumers who deserve access to real science-backed solutions.” – Darren Lopez, CEO
• Management highlights MODS Max as the core enabler of three value drivers: testosterone optimization (NHTO/TPrime365), NAD+ and cellular health formulations, and platform licensing/peptide delivery opportunities.
• Leadership plans further systems upgrades (NetSuite AI tools in 2026) and controlled scaling via pharmacy partnerships to protect brand integrity and pricing.

Industry Context

StockSavvy.ai notes growing investor interest in proprietary delivery platforms (e.g., oral peptide delivery) and science-led wellness brands, underscored by Merck’s up-to-$493M license deal with Cyprumed and L Catterton’s $680M take-private of Thorne HealthTech. However, OTC-listed microcaps face liquidity frictions from penny stock rules and Rule 15c2-11 compliance, which can mute valuation despite operational progress.

Comparison to Industry Standards

• Revenue growth: A 208% YoY increase outpaces typical supplement and wellness peers, where mid-teens to low-double-digit growth is more common among established brands (e.g., Thorne HealthTech pre-deal).
• Profitability: An ~11.3% net margin is competitive for DTC/wholesale hybrid supplement businesses, though leaders often target higher EBITDA margins via scale; the company’s ~57% gross margin aligns with premium nutraceutical peers.
• Valuation context cited: Supplement producers at ~10.7x EV/EBITDA and ~6.7x EV/Revenue; compounding pharmacies at ~11.1x EV/EBITDA and ~6.6x EV/Revenue (per management’s market references).
• Platform deals: Merck/Cyprumed’s up-to-$493M oral peptide platform license and L Catterton’s $680M acquisition of Thorne suggest strategic appetite for scalable IP and science-led wellness channels.
• NAD+ peer benchmark: Niagen Bioscience (formerly ChromaDex) focused solely on NAD+ reportedly carries a ~$390–$812M market cap (as referenced), highlighting investor interest in validated cellular health franchises.

Corporate Governance

Legal Proceedings

• No legal proceedings or governmental regulatory proceedings disclosed.

Related Party Transactions

• Purchased $2,665,950 of inventory from Ageless Holdings, LLC in 2025; Ageless is 90% owned by the CEO.
• Received $380,130 of advances from entities owned/controlled by management/board in 2025; repaid $3,162,000, resulting in an overpayment of $137,717 at 12/31/2025.
• In 2024, purchased $444,785 of inventory from Ageless; received $518,063 of advances and repaid $1,071,720 (overpayment of $21,798 at 12/31/2024).
• Company is undertaking a formal separation from Ageless Holdings, including transfer of WIP inventory to the Company and issuance of preferred shares to the CEO tied to R&D and 30+ proprietary formulations (settlement terms being finalized).

Stakeholder Impact

• Shareholders: Strong revenue and profit trends are positive, but planned capital raises and potential reverse split introduce dilution and pricing risk.
• Employees: Investments in ERP and operations support scalability and may improve productivity and controls.
• Customers: Amazon pivot to Rebelution/Growvana and pharmacy partnerships aim to improve availability, education, and fulfillment quality.
• Suppliers/Partners: Separation from Ageless may reduce conflicts and create more arm’s-length arrangements.
• Creditors: Improved working capital and cash generation reduce near-term liquidity risk, though growth plans rely on external capital.

Next Steps

• Complete the $1.5M Reg A offering and pursue a $5–$7.5M raise tied to a major exchange uplist.
• Evaluate and potentially execute a reverse stock split to meet exchange requirements.
• Implement NetSuite AI tools in 2026 to enhance forecasting and automate financial processes.
• Advance pharmacy partnerships to scale MODS Max formulations in a controlled, compliant manner.
• Execute Amazon pivot to Rebelution/Growvana for marketplace optimization and scaled DTC execution.
• Finalize settlement and separation from Ageless Holdings, including transfer of WIP inventory and issuance of preferred shares tied to 30+ proprietary formulations.
• Continue IP expansion and pursue platform licensing opportunities (including oral delivery of peptides/GLP-1).

Key Dates

Recommendation

Rapid growth and a swing to double-digit net margins are encouraging, and the roadmap (capital raises, uplist, channel and platform expansion) is clear. However, material internal control weaknesses, reliance on related parties, OTC/penny stock constraints, and expected dilution warrant caution until governance is strengthened and capital plans are executed on favorable terms.

Keywords

BioScience Health Innovations, Best 365 Labs, MODS Max, testosterone optimization, NAD+, peptides, GLP-1, Reg A offering, Oracle NetSuite, OTC Pink, reverse stock split, uplist, related party transactions, material weaknesses, health and wellness